Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Myasthenia Gravis, Generalized Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Ravulizumab, Placebo
Biological · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
49
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Refractory Generalized Myasthenia Gravis
Interventions
Eculizumab, Placebo
Biological · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced May 22, 2026, 12:14 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
Interventions
Efgartigimod IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Scottsdale, Arizona • Fresno, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Placebo, Cladribine Low Dose, Cladribine High Dose
Other · Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • Longmont, Colorado • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
TAK-079, TAK-079 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced May 22, 2026, 12:14 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG
Interventions
Efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Carlsbad, California • Orange, California • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced May 22, 2026, 12:14 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
Interventions
Efgartigimod IV, Empasiprubart IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Carlsbad, California • Miami, Florida • Columbia, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Charlotte, North Carolina • Denton, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
2 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Whole-body Electrical Muscle Stimulation Exercise
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Fairway, Kansas • Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced May 22, 2026, 12:14 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Interventions
Ultomiris
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
mycophenolate mofetil (CellCept), placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Sun City, Arizona • Sacramento, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2008 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Inebilizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Generalized Myasthenia Gravis (gMG)
Interventions
Zilucoplan®
Drug
Lead sponsor
Miriam Freimer
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Generalized Myasthenia Gravis, Myasthenia Gravis
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 130 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Orange, California • San Francisco, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Myasthenia Gravis, Generalized Myasthenia Gravis
Interventions
Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101
Drug · Biological
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Orange, California • Palo Alto, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Fresno, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Myasthenia Gravis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 22, 2026, 12:14 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
DNTH103, Placebo
Drug
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • Stamford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Myasthenia Gravis Generalised
Interventions
mycophenolate mofetil [CellCept], Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Sun City, Arizona • Sacramento, California • Upland, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Denton, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 12:14 AM EDT